The number of visits to dermatologists for atopic dermatitis and eczema may have increased during the summer months of 2023 following the Canadian wildfires.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Discover the potential of cendakimab, an anti–interleukin-13 monoclonal antibody, to improve symptoms in adult patients with moderate to severe atopic dermatitis, as demonstrated in a recent phase II clinical trial published in JAMA Dermatology.
Topical delgocitinib improved eczema severity scores and caused fewer adverse events than oral alitretinoin in adults with severe chronic hand eczema, according to a phase 3 study.
From new conferences and OCT systems to the links between pediatric uveitis and early-onset atopic dermatitis, these are the news stories and studies that caught our attention this week…